 Seres Therapeutics NASDAQ:MCRB shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres Therapeutics stock has been rising Wednesday, up 17.49 to a price of 6.42. 